CO6220929A2 - Composicion complementaria para el tratamiento de enfermedades oculares - Google Patents
Composicion complementaria para el tratamiento de enfermedades ocularesInfo
- Publication number
- CO6220929A2 CO6220929A2 CO09073309A CO09073309A CO6220929A2 CO 6220929 A2 CO6220929 A2 CO 6220929A2 CO 09073309 A CO09073309 A CO 09073309A CO 09073309 A CO09073309 A CO 09073309A CO 6220929 A2 CO6220929 A2 CO 6220929A2
- Authority
- CO
- Colombia
- Prior art keywords
- composition according
- vitamin
- copper
- substantially consists
- omega
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/30—Copper compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
1.- Una composición que comprende en una base de dosis diaria: aproximadamente de 40 - 80 mg, de preferencia de 40 - 60 mg de vitamina C; aproximadamente de 15 - 25 mg, de preferencia de 15 - 20 mg de vitamina E; aproximadamente de 7- 14 mg, de preferencia de 7- 11 mg de luteína; aproximadamente de 8 - 15 mg, de preferencia de 8 - 13 mg de zinc; aproximadamente de 100 - 300 mg de ácido graso omega-3, y opcionalmente alrededor de 0.1 - 0.3 mg, de preferencia 0.25 mg de cobre. 2.- Una composición de acuerdo con la reivindicación 1, en donde dicho cobre está presente. 3.- Una composición de acuerdo con la reivindicación 1, en donde dicho cobre está ausente. 4.- Una composición de acuerdo con la reivindicación 1, que comprende zeaxantina, de preferencia en una cantidad de aproximadamente 100 a 2000 microgramos (0.1-2 mg), muy preferiblemente en una cantidad de alrededor de 100 a 1000 microgramos (0.1-1 mg). 5.- Una composición de acuerdo con la reivindicación 1, en donde dicho ácido graso omega-3 comprende ácido docosahexaenoico (DHA) y ácido eicosapentaenoico (EPA). 6.- Una composición de acuerdo con la reivindicación 1, en donde dicho ácido graso omega-3 proviene de aceite de pescado con un contenido de 70% en peso de DHA. 7.- Una composición de acuerdo con la reivindicación 1, en donde dicha vitamina C comprende o substancialmente consiste de ascorbato de calcio, dicha vitamina E comprende o substancialmente consiste de acetato de d,l-alfa tocoferilo, dicho zinc comprende o substancialmente consiste de óxido de zinc, y dicho cobre comprende o substancialmente consiste de carbonato cúprico básico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06126261A EP1932521A1 (en) | 2006-12-15 | 2006-12-15 | Nutritional supplement composition for treatment of ocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6220929A2 true CO6220929A2 (es) | 2010-11-19 |
Family
ID=38024441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09073309A CO6220929A2 (es) | 2006-12-15 | 2009-07-15 | Composicion complementaria para el tratamiento de enfermedades oculares |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20100028459A1 (es) |
| EP (2) | EP1932521A1 (es) |
| JP (1) | JP2010513248A (es) |
| KR (1) | KR20090089473A (es) |
| CN (1) | CN101557807A (es) |
| AR (1) | AR064332A1 (es) |
| AU (1) | AU2007331432A1 (es) |
| BR (1) | BRPI0720046A2 (es) |
| CA (1) | CA2672013A1 (es) |
| CL (1) | CL2007003630A1 (es) |
| CO (1) | CO6220929A2 (es) |
| EC (1) | ECSP099516A (es) |
| GT (1) | GT200900161A (es) |
| MA (1) | MA30994B1 (es) |
| MX (1) | MX2009006306A (es) |
| NO (1) | NO20092633L (es) |
| PE (1) | PE20081580A1 (es) |
| RU (1) | RU2009126735A (es) |
| TN (1) | TN2009000241A1 (es) |
| TW (1) | TW200843725A (es) |
| WO (1) | WO2008071775A1 (es) |
| ZA (1) | ZA200903862B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8389504B2 (en) * | 2008-05-08 | 2013-03-05 | Mead Johnson Nutrition Company | Prenatal dietary supplement |
| WO2010074940A1 (en) * | 2008-12-23 | 2010-07-01 | Alcon Research, Ltd. | Compositions and nutritional supplements for improving ocular health and reducing ocular inflammatory response |
| US20130295171A1 (en) | 2009-07-23 | 2013-11-07 | U.S NUTRACEUTICALS, LLC d/b/a Valensa International | Krill oil and reacted astaxanthin composition and associated method |
| US20110021465A1 (en) * | 2009-07-23 | 2011-01-27 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome |
| US20130011469A1 (en) | 2009-07-23 | 2013-01-10 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Krill oil and carotenoid composition, associated method and delivery system |
| US20110237548A1 (en) * | 2009-07-23 | 2011-09-29 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline |
| CN103796717A (zh) * | 2011-07-07 | 2014-05-14 | 霍华德基金会控股有限公司 | 视觉功效和/或黄斑色素沉着的改善或与之相关的改善 |
| US9115078B2 (en) | 2011-07-18 | 2015-08-25 | Physicians Recommended Nutriceuticals, Llc | Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands |
| US20210121430A1 (en) | 2011-07-18 | 2021-04-29 | Prn Physician Recommended Nutriceuticals, Llc | Omega-3 fatty acid supplementation for use in treating dry eye |
| US9381183B2 (en) | 2012-07-18 | 2016-07-05 | Physicians Recommended Nutriceuticals, Llc | Methods for improving the quality of the meibum composition of meibomian glands |
| US10709680B2 (en) | 2011-07-18 | 2020-07-14 | Physicians Recommended Nutriceuticals, Llc | Methods for treating dry eye |
| JP2016508955A (ja) * | 2011-09-12 | 2016-03-24 | ジョルジオ タソスＧＥＯＲＧＩＯＵ， Ｔａｓｓｏｓ | 疾病治療用オメガ脂肪酸の使用 |
| CN102538980A (zh) * | 2012-01-12 | 2012-07-04 | 杭州美盛红外光电技术有限公司 | 热像装置和热像拍摄方法 |
| JP2016185939A (ja) * | 2015-03-27 | 2016-10-27 | ロート製薬株式会社 | 経口組成物 |
| JP2016190829A (ja) * | 2015-03-31 | 2016-11-10 | ウィルファーム株式会社 | 活性型ｄｈａを含む製剤、強化食品、サプリメント並びに化粧品 |
| JP6056114B2 (ja) * | 2015-05-30 | 2017-01-11 | 富田製薬株式会社 | 油状物質含有粉末組成物 |
| CN108208804A (zh) * | 2018-01-05 | 2018-06-29 | 美博迪尔（北京）生物科技有限公司 | 一种缓解眼睛干涩、抵御蓝光损伤及保护眼底的组合物及其制备方法 |
| CN108096288A (zh) * | 2018-01-16 | 2018-06-01 | 南京圣诺生物科技实业有限公司 | 护眼片及其制备方法和应用 |
| EP4117652A1 (en) * | 2020-03-11 | 2023-01-18 | Bausch + Lomb Ireland Limited | Compositions and methods for eye health comprising very long chain fatty acids |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003003981A2 (en) * | 2001-07-05 | 2003-01-16 | Vital Basics, Inc. | Compositions for improving mental performance |
| US6649195B1 (en) * | 2002-07-11 | 2003-11-18 | Vitacost.Com, Inc. | Eyesight enhanced maintenance composition |
| US20050112210A1 (en) * | 2003-09-12 | 2005-05-26 | Terry Grossman | Eye nutritional supplement |
| WO2005110375A1 (en) * | 2004-05-08 | 2005-11-24 | Paul Edward L Jr | Nutritional supplement for treatment of ocular diseases |
| DE202005012984U1 (de) * | 2005-08-17 | 2005-11-24 | W & B Pharmamarken Gmbh | Arzneimittel- und Nahrungsergänzungsmittelkombinationen zur Behandlung von Augenerkrankungen |
| EP1962618A2 (en) * | 2005-12-20 | 2008-09-03 | Alcon Research, Ltd. | Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision |
-
2006
- 2006-12-15 EP EP06126261A patent/EP1932521A1/en not_active Ceased
-
2007
- 2007-12-13 RU RU2009126735/15A patent/RU2009126735A/ru not_active Application Discontinuation
- 2007-12-13 KR KR1020097014635A patent/KR20090089473A/ko not_active Application Discontinuation
- 2007-12-13 CN CNA2007800457551A patent/CN101557807A/zh active Pending
- 2007-12-13 JP JP2009540779A patent/JP2010513248A/ja active Pending
- 2007-12-13 PE PE2007001783A patent/PE20081580A1/es not_active Application Discontinuation
- 2007-12-13 AU AU2007331432A patent/AU2007331432A1/en not_active Abandoned
- 2007-12-13 WO PCT/EP2007/063908 patent/WO2008071775A1/en active Application Filing
- 2007-12-13 US US12/518,508 patent/US20100028459A1/en not_active Abandoned
- 2007-12-13 AR ARP070105598A patent/AR064332A1/es unknown
- 2007-12-13 MX MX2009006306A patent/MX2009006306A/es not_active Application Discontinuation
- 2007-12-13 CA CA002672013A patent/CA2672013A1/en not_active Abandoned
- 2007-12-13 EP EP07857555A patent/EP2094252A1/en not_active Withdrawn
- 2007-12-13 BR BRPI0720046-3A2A patent/BRPI0720046A2/pt not_active Application Discontinuation
- 2007-12-14 CL CL200703630A patent/CL2007003630A1/es unknown
- 2007-12-14 TW TW096148104A patent/TW200843725A/zh unknown
-
2009
- 2009-06-03 ZA ZA200903862A patent/ZA200903862B/xx unknown
- 2009-06-12 TN TNP2009000241A patent/TN2009000241A1/fr unknown
- 2009-06-12 GT GT200900161A patent/GT200900161A/es unknown
- 2009-06-15 MA MA31993A patent/MA30994B1/fr unknown
- 2009-07-10 NO NO20092633A patent/NO20092633L/no not_active Application Discontinuation
- 2009-07-15 EC EC2009009516A patent/ECSP099516A/es unknown
- 2009-07-15 CO CO09073309A patent/CO6220929A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MA30994B1 (fr) | 2009-12-01 |
| TN2009000241A1 (en) | 2010-10-18 |
| TW200843725A (en) | 2008-11-16 |
| PE20081580A1 (es) | 2009-01-01 |
| BRPI0720046A2 (pt) | 2013-12-24 |
| EP2094252A1 (en) | 2009-09-02 |
| CA2672013A1 (en) | 2008-06-19 |
| JP2010513248A (ja) | 2010-04-30 |
| MX2009006306A (es) | 2009-06-23 |
| CN101557807A (zh) | 2009-10-14 |
| EP1932521A1 (en) | 2008-06-18 |
| ECSP099516A (es) | 2009-08-28 |
| RU2009126735A (ru) | 2011-01-20 |
| CL2007003630A1 (es) | 2008-08-08 |
| ZA200903862B (en) | 2010-05-26 |
| KR20090089473A (ko) | 2009-08-21 |
| WO2008071775A1 (en) | 2008-06-19 |
| GT200900161A (es) | 2009-11-30 |
| AR064332A1 (es) | 2009-04-01 |
| US20100028459A1 (en) | 2010-02-04 |
| NO20092633L (no) | 2009-07-10 |
| AU2007331432A1 (en) | 2008-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6220929A2 (es) | Composicion complementaria para el tratamiento de enfermedades oculares | |
| Walingo | Role of vitamin C (ascorbic acid) on human health-a review | |
| NZ600167A (en) | Concentrated therapeutic phospholipid compositions | |
| MXPA04009765A (es) | Metodo para mejorar la absorcion de la vitamina e por una mascota animal. | |
| EA200700240A1 (ru) | Композиция, содержащая статины и омега - 3 жирные кислоты | |
| BRPI0416403A (pt) | composição de óleo enriquecida em diglicerìdeo com ácido linoléico conjugado | |
| CN102318742B (zh) | 抗氧化保健鸡蛋的生产方法及其使用的复合抗氧化剂 | |
| WO2012139132A1 (en) | Methods and compositions to promote ocular health | |
| US20080138417A1 (en) | Topical Composition And Method Of Forming | |
| EA200801602A1 (ru) | Эмульсия | |
| AR062305A1 (es) | Metodos para mejorar la salud osea y la salud muscular | |
| RU2009126740A (ru) | Композиция питательной добавки, предназначенная для лечения глазных болезней | |
| RU2011129617A (ru) | Кормовая композиция, содержащая антиоксидант, предназначенная для усиления противовирусного иммунитета у животных-компаньонов | |
| RU2008144576A (ru) | Пероральная композиция с эффектом, направленным против старения кожи | |
| BR0309089A (pt) | Métodos dietéticos para melhoria de desempenho em cães | |
| AU2014242655A1 (en) | Neuroprotective effect of carotenoids in brain | |
| Guo et al. | Antioxidant and anti‐inflammatory effects of different zinc sources on diquat‐induced oxidant stress in a piglet model | |
| BRPI0921565A8 (pt) | Soluções de microelementos e respectivos métodos de preparação e de suprimento de microelementos a animais. | |
| NZ627354A (en) | Organic emulsion comprising dha and epa | |
| AR063929A1 (es) | Formulacion parenteral oleosa para intensificacion del desempeno reproductivo de animales de produccion | |
| IT1392084B1 (it) | Composizione immuno-nutrizionale | |
| CL2009000230A1 (es) | Composicion de suplemento nutricional o dietetico que comprende vitamina c, vitamina e, luteina, zinc, acidos grasos omega 3 y cobre; metodo de fabricacion; uso para el tratamiento y/o prevencion de la degeneracion macular relacionada con la edad y retinopatia diabetica. | |
| IT201800000890A1 (it) | Composizione nutraceutica per l’attivazione delle sirtuine con effetto anti-aging/reverse-aging | |
| CA2681514C (en) | Use of a masked or coated copper salt for the treatment of macular degeneration | |
| Mandelker | Cellular effects of common antioxidants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |